Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care

Similar documents
2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

Measure #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clincal Care

Quality ID #439: Age Appropriate Screening Colonoscopy National Quality Strategy Domain: Efficiency and Cost Reduction

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2017 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process

Measure #425: Photodocumentation of Cecal Intubation National Quality Strategy Domain: Effective Clinical Care

Measure #425: Photodocumentation of Cecal Intubation National Quality Strategy Domain: Effective Clinical Care

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines

Quality ID #113 (NQF 0034): Colorectal Cancer Screening National Quality Strategy Domain: Effective Clinical Care

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

Quality ID #342: Pain Brought Under Control Within 48 Hours National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

GIQIC18 Appropriate follow-up interval of not less than 5 years for colonoscopies with findings of 1-2 tubular adenomas < 10 mm

Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care

Quality ID #413: Door to Puncture Time for Endovascular Stroke Treatment National Quality Strategy Domain: Effective Clinical Care

Quality ID #113 (NQF 0034): Colorectal Cancer Screening National Quality Strategy Domain: Effective Clinical Care

Measure #164 (NQF 0129): Coronary Artery Bypass Graft (CABG): Prolonged Intubation National Quality Strategy Domain: Effective Clinical Care

Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

Objectives. Definitions. Colorectal Cancer Screening 5/8/2018. Payam Afshar, MS, MD Kaiser Permanente, San Diego. Colorectal cancer background

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

Quality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination

Measure #409: Clinical Outcome Post Endovascular Stroke Treatment National Quality Strategy Domain: Effective Clincial Care

Title Description Type / Priority

DESCRIPTION: Percentage of patients aged 18 years and older undergoing isolated CABG surgery who received an IMA graft

Measure #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care

Quality ID #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care

Colon Cancer Screening. Layth Al-Jashaami, MD GI Fellow, PGY 4

DENOMINATOR: Patients aged 18 and older with infrarenal non-ruptured endovascular AAA repairs

DESCRIPTION: Percent of asymptomatic patients undergoing CEA who are discharged to home no later than post-operative day #2

Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care

Quality ID #117 (NQF 0055): Diabetes: Eye Exam National Quality Strategy Domain: Effective Clinical Care

Quality ID #263: Preoperative Diagnosis of Breast Cancer National Quality Strategy Domain: Effective Clinical Care

6 semanas de embarazo. Tubulovillous adenoma with dysplasia icd 10. Inicio / Embarazo / 6 semanas de embarazo

Quality ID #187: Stroke and Stroke Rehabilitation: Thrombolytic Therapy National Quality Strategy Domain: Effective Clinical Care

Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer

Measure #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination

Measure #408: Opioid Therapy Follow-up Evaluation National Quality Strategy Domain: Effective Clinical Care

Supplementary Appendix

DENOMINATOR: All female patients aged 65 years and older with a visit during the measurement period

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Quality ID #414: Evaluation or Interview for Risk of Opioid Misuse National Quality Strategy Domain: Effective Clinical Care

Measure #355: Unplanned Reoperation within the 30 Day Postoperative Period National Quality Strategy Domain: Patient Safety

Screening & Surveillance Guidelines

DENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis

If multiple KRAS mutation tests have been performed, refer to the most recent test results.

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Quality ID #457 (NQF 0216): Proportion Admitted to Hospice for less than 3 days- National Quality Strategy Domain: Effective Clinical Care

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

Quality ID #110 (NQF 0041): Preventive Care and Screening: Influenza Immunization National Quality Strategy Domain: Community/Population Health

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

Measure #167 (NQF 0114): Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure National Quality Strategy Domain: Effective Clinical Care

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

CLINICAL PRACTICE GUIDELINE FOR COLORECTAL CANCER SCREENING

Measure #110 (NQF 0041): Preventive Care and Screening: Influenza Immunization National Quality Strategy Domain: Community/Population Health

Measure #265: Biopsy Follow-Up National Quality Strategy Domain: Communication and Care Coordination

DENOMINATOR: All patients 18 and older prescribed opiates for longer than six weeks duration

WEO CRC SC Meeting. Barcelona, Spain October 23, 2015

Quality ID #236 (NQF 0018): Controlling High Blood Pressure National Quality Strategy Domain: Effective Clinical Care

Pathology in Slovenian CRC screening programme:

Measure #402: Tobacco Use and Help with Quitting Among Adolescents National Quality Strategy Domain: Community / Population Health

Quality ID#164 (NQF 0129): Coronary Artery Bypass Graft (CABG): Prolonged Intubation National Quality Strategy Domain: Effective Clincial Care

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

DENOMINATOR: All patients undergoing anterior or apical pelvic organ prolapse (POP) surgery

Colorectal Cancer Screening

Quality ID# 406: Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients National Quality Strategy Domain: Effective Clinical Care

DENOMINATOR: Adult patients with metastatic colorectal cancer who have a RAS (KRAS or NRAS) gene mutation

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

Measure #405: Appropriate Follow-up Imaging for Incidental Abdominal Lesions National Quality Strategy Domain: Effective Clinical Care

Quality ID #112 (NQF 2372): Breast Cancer Screening National Quality Strategy Domain: Effective Clinical Care

Quality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination

Quality ID #225 (NQF 0509): Radiology: Reminder System for Screening Mammograms National Quality Strategy Domain: Communication and Care Coordination

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Measure #265: Biopsy Follow-Up National Quality Strategy Domain: Communication and Care Coordination

Patologia sistematica V Gastroenterologia Prof. Stefano Fiorucci. Colon polyps. Colorectal cancer

Measure #340 (NQF 2079): HIV Medical Visit Frequency - National Quality Strategy Domain: Efficiency And Cost Reduction

Colonoscopy MM /01/2010. PPO; HMO; QUEST Integration 10/01/2017 Section: Surgery Place(s) of Service: Outpatient

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Measure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

Quality ID #168 (NQF 0115): Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration National Quality Strategy Domain: Effective Clinical Care

Quality ID #1 (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%) National Quality Strategy Domain: Effective Clinical Care

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

Quality ID #291: Parkinson s Disease: Cognitive Impairment or Dysfunction Assessment National Quality Strategy Domain: Effective Clinical Care

Surveying the Colon; Polyps and Advances in Polypectomy

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

DENOMINATOR: All melanoma pathology reports for primary malignant cutaneous melanoma

DENOMINATOR: All patients aged 18 years and older seen for at least two visits or at least one preventive visit during the measurement period

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

DESCRIPTION: Percentage of final reports for screening mammograms that are classified as probably benign

Transcription:

Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION: The percentage of patients age 50 years or older with at least one conventional adenoma or colorectal cancer detected during screening colonoscopy INSTRUCTIONS: This measure is to be submitted each time a screening colonoscopy for colorectal cancer is performed during the performance period. This measure may be submitted by eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding. Measure Submission The listed denominator criteria is used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions allowed by the measure. The quality-data codes listed do not need to be submitted for registry submissions; however, these codes may be submitted for those registries that utilize claims data. DENOMINATOR: Patients age 50 years or older undergoing a screening colonoscopy DENOMINATOR NOTE: The intention of the measure is to identify patients with an adenoma(s) or colorectal cancer detected during a screening colonoscopy. A patient with a family history of colon neoplasia, but no personal history of colon neoplasm would be eligible for the denominator criteria population for this measure. Patients with a personal history of colon neoplasia, colonic polyps, colon cancer, or other malignant neoplasm of the rectum, rectosigmoid junction or anus would not be eligible for denominator and would qualify for the Denominator Exclusion code G9936. In order to submit the Denominator Exclusion code G9937, the primary indication for the colonoscopy exam would be a diagnostic indication (i.e., a colonoscopy performed on a patient who has past and/or present gastrointestinal symptoms, polyps, GI disease, iron-deficiency anemia, and/or any other abnormal tests). Definition: Colorectal Cancer Precursor Lesions- Based on pathologic diagnosis, colorectal cancer precursor lesions include: adenomatous polyps [high-grade dysplasia, tubular, tubulovillous, villous] and traditional serrated adenomas, sessile serrated polyps and sessile serrated adenomas. Screening Colonoscopy Exams For purposes of this measure, the primary indication of a colonoscopy is screening when the procedure is performed to detect polyps/lesions in the absence of signs, symptoms, or personal history of colon neoplasia, even if during the screening colonoscopy polyps are found, removed or biopsied. If the primary indication for performing the colonoscopy is diagnostic or surveillance then the patient would not meet the intent of the measure. Diagnostic Colonoscopy Exams- For purposes of this measure, the primary indication of a colonoscopy is diagnostic if the procedure is performed on a patient for the purpose of evaluating past and/or present gastrointestinal symptoms, polyps, GI disease, iron-deficiency anemia, and/or any other abnormal tests (e.g., positive fecal occult blood, abnormal radiographic/imaging studies, or abnormal genetic material). Surveillance Colonoscopy Exams (i.e., Patients with Personal History of Colonic Polyps, Colon Cancer, or Other Malignant Neoplasm of Rectum, Rectosigmoid Junction, and Anus) - A surveillance colonoscopy can be performed at varying ages and intervals based on the patient's personal history of colon Page 1 of 8

cancer, polyps, and/or gastrointestinal disease. Colonoscopy for patients with a history of colon polyp(s) is identified as a surveillance colonoscopy rather than a screening colonoscopy. The following codes are included in the Denominator Exclusion (G9936) to assist with identifying a personal polyp history: Z85.038, Z85.048, Z86.010 Denominator Criteria (Eligible Cases): Patients 50 years of age or older on date of encounter AND Risk factors for colorectal cancer (ICD-10-CM): Z80.0, Z83.71, Z12.11 AND Patient procedure during performance period (CPT or HCPCS): 45378, 45380, 45381, 45384, 45385, G0121 WITHOUT Modifiers: 52, 53, 73, or 74 AND NOT DENOMINATOR EXCLUSION: Surveillance colonoscopy --- Personal history of colonic polyps, colon cancer, or other malignant neoplasm of rectum, rectosigmoid junction, and anus: G9936 AND NOT DENOMINATOR EXCLUSION: Diagnostic colonoscopy: G9937 NUMERATOR: Number of patients age 50 years or older with at least one conventional adenoma or colorectal cancer detected during screening colonoscopy OR OR Numerator Options: Performance Met: Denominator Exception: Performance Not Met: Adenoma(s) or colorectal cancer detected during screening colonoscopy (G9933) Documentation that neoplasm detected is only diagnosed as traditional serrated adenoma, sessile serrated polyp, or sessile serrated adenoma (G9934) Adenoma(s) or colorectal cancer not detected during screening colonoscopy (G9935) RATIONALE: The removal of adenomatous polyps during a screening colonoscopy is associated with a lower risk of subsequent colorectal cancer incidence and mortality. Higher adenoma detection rates (> 25% in a mixed gender population) are associated with significant protection against incident colorectal cancer in the five years following screening colonoscopy. CLINICAL RECOMMENDATION STATEMENTS: The United States Preventive Services Task Force has recommended screening colonoscopy for adults, beginning at age 50 and continuing until age 75 (Grade A recommendation) Screening exams are those performed to detect lesions in the absence of signs, symptoms, or personal history of colon neoplasia. The adenoma detection rate is an independent predictor of risk of developing colorectal cancer between screening colonoscopies. However, studies have documented wide variation in adenoma detection rates, illustrating the need for measuring and monitoring this metric for endoscopists. Some studies have identified variation due to the location of adenomas. Procedure length has also been Page 2 of 8

found in some, but not all, studies to correlate with adenoma detection rate. The adenoma detection rate varies between genders, with a lower rate demonstrated in women. Multi-specialty and stakeholder guidelines support the importance of measuring the adenoma detection rate in the prevention of colorectal cancer. Guidelines and the supporting literature support performance targets for adenoma detection rate of 25% for a mixed gender population (20% in women and 30% in men). The performance targets for adenoma detection rate were established by using studies reporting detection of conventional adenomas. Serrated lesions are a separate class from conventional adenomas. Sessile serrated polyp/adenoma differentiation from hyperplastic polyp (i.e., the only class of colorectal polyps not considered to have a risk of becoming cancer) is subject to marked interobserver variation in pathologic interpretation. Thus, serrated lesions should not be counted toward the ADR. Hyperplastic polyps should also not be counted toward the ADR as they are not considered to have a risk of becoming cancer. COPYRIGHT: American College of Gastroenterology, American Gastroenterological Association and American Society for Gastrointestinal Endoscopy, 2015. All rights reserved. Page 3 of 8

Page 4 of 8

Page 5 of 8

2018 Registry Flow for Quality ID #343: Screening Colonoscopy Adenoma Detection Rate Please refer to the specific section of the Measure Specification to identify the denominator and numerator information for use in submitting this Individual Specification. This flow is for registry data submission. 1. Start with Denominator 2. Check Patient Age: a. If Patient Age is greater than or equal to 50 Years of age on Date of Service during Performance Period equals No, do not include in Eligible Population. Stop Processing. b. If Patient Age is greater than or equal to 50 Years of age on Date of Service during Performance Period equals Yes, proceed to check Patient Diagnosis. 3. Check Patient Diagnosis: a. If Diagnosis for Risk Factors for Colorectal Cancer as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing. b. If Diagnosis for Risk Factors for Colorectal Cancer as Listed in the Denominator equals Yes, proceed to check Procedure Performed. 4. Check Procedure Performed: a. If Procedure as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing. b. If Procedure as Listed in the Denominator equals Yes, proceed to check Modifiers: 52, 53, 73 or 74. 5. Check Modifiers: 52, 53, 73 or 74: a. If Modifiers: 52, 53, 73 or 74 equals Yes, do not include in Eligible Population. Stop Processing. b. If Modifiers: 52, 53, 73 or 74 equals No, proceed to check Diagnostic Colonoscopy Exclusion. 6. Check Diagnostic Colonoscopy: a. If Diagnostic Colonoscopy equals Yes, do not include in Eligible Population. Stop Processing. b. If Diagnostic Colonoscopy equals No, proceed to check Surveillance Colonoscopy Exclusion. 7. Check Surveillance Colonoscopy: a. If Surveillance Colonoscopy equals Yes, do not include in Eligible Population. Stop Processing. b. If Surveillance Colonoscopy equals No, proceed to check Denominator Population. 8. Denominator Population Page 6 of 8

a. Denominator population is all Eligible Patients in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 130 procedures in the Sample Calculation. 9. Start Numerator 10. Check Adenoma(s) or Colorectal Cancer Detected During Screening Colonoscopy: a. If Adenoma(s) or Colorectal Cancer Detected During Screening Colonoscopy equals Yes, include in Data Completeness Met and Performance Met. b. Data Completeness Met and Performance Met letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 50 procedures in the Sample Calculation. c. If Adenoma(s) or Colorectal Cancer Detected During Screening Colonoscopy equals No, proceed to check Documentation that Neoplasm Detected is Only Diagnosed as Traditional Serrated Adenoma, Sessile Serrated Polyp, or Sessile Serrated Adenoma. 11. Check Documentation that Neoplasm Detected is Only Diagnosed as Traditional Serrated Adenoma, Sessile Serrated Polyp, or Sessile Serrated Adenoma: a. If Documentation that Neoplasm Detected is Only Diagnosed as Traditional Serrated Adenoma, Sessile Serrated Polyp, or Sessile Serrated Adenoma equals Yes, include in Data Completeness Met and Denominator Exception. b. Data Completeness Met and Denominator Exception letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter b equals 50 procedures in the Sample Calculation. c. If Documentation that Neoplasm Detected is Only Diagnosed as Traditional Serrated Adenoma, Sessile Serrated Polyp, or Sessile Serrated Adenoma equals No, proceed to check Adenoma(s) or Colorectal Cancer not Detected During Screening Colonoscopy 12. Check Adenoma(s) or Colorectal Cancer not Detected During Screening Colonoscopy: a. If Adenoma(s) or Colorectal Cancer not Detected During Screening Colonoscopy equals Yes, include in Data Completeness Met and Performance Not Met. b. Data Completeness Met and Performance Not Met letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter c equals 20 procedures in the Sample Calculation. c. If Adenoma(s) or Colorectal Cancer not Detected During Screening Colonoscopy equals No, proceed to Data Completeness Not Met. 13. Check Data Completeness Not Met a. If Data Completeness Not Met, the Quality Data Code or equivalent was not submitted. 10 procedures have been subtracted from the Data Completeness Numerator in the Sample Calculation. Page 7 of 8

Page 8 of 8